Leading bank backs European pharma as the cleaner alternative to the AI trade

UBS reiterated an overweight stance on European pharmaceuticals, positioning the sector as a more resilient place to deploy capital versus artificial intelligence as broader markets slow. The bank said the investment case is now driven by fundamentals beyond just “defensive quality,” implying better risk-adjusted support for the group.

Analysis

UBS reiterated an overweight stance on European pharmaceuticals, positioning the sector as a more resilient place to deploy capital versus artificial intelligence as broader markets slow. The bank said the investment case is now driven by fundamentals beyond just “defensive quality,” implying better risk-adjusted support for the group.